Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business OfficerRead More
Harnessing our breakthrough technologies and building a team of the best and brightest professionals — unafraid of pushing the limits on what our technology can do — Selexis has become the scientific pioneer and global leader in mammalian cell line generation. Today, the name Selexis is synonymous with excellence in our field.
Our global leadership position was born from our initial vision and commitment to bring change to an industry that continually requires unrelenting urgency and a bold pace of innovation. Patients’ lives depend on it. They can’t wait, and neither will we.
Continued advances in technologies and methods for protein expression are critical for further development of medicines that are based on recombinant proteins, such as monoclonal antibodies and difficult-to-express proteins, including Fc-fusion, bi-specific monoclonal antibodies, and novel scaffolds. This is where our expertise truly makes a difference.
Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for nearly two decades. Our proprietary SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization. The strength and utility of SUREtechnology is evidenced through results from our 2019 customer survey. Ninety-three percent of respondents said they would work with Selexis again and would recommend Selexis.